Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Figure 1

Comparison of serum tumor marker levels after treatment (mean ± SD). (a) Comparison of CEA levels. The abscissa was STG and CTG, and the ordinate was the CEA level (ng/ml). The CEA levels in the STG and CTG were 76.26 ± 3.64 ng/ml and 44.35 ± 3.48 ng/ml. indicated a remarkable difference in the CEA levels between the two groups after treatment (t = 42.032,  < 0.001). (b) Comparison of CYFRA 21-1 levels. The abscissa was STG and CTG, and the ordinate was the CYFRA 21-1 level (ng/ml). The CYFRA 21-1 levels in the STG and CTG were 16.74 ± 1.35 ng/ml and 10.32 ± 1.28 ng/ml. indicated a remarkable difference in the CYFRA 21-1 levels between the two groups after treatment (t = 22.891,  < 0.001). (c) Comparison of NSE levels. The abscissa was STG and CTG, and the ordinate was the NSE level (ng/ml). The NSE levels in the STG and CTG were 24.16 ± 2.43 ng/ml and 12.54 ± 2.56 ng/ml. indicated a remarkable difference in the NSE levels between the two groups after treatment (t = 21.837,  < 0.001).

(a)

(b)

(c)